how common is progesterone related gyno from fina
- Thread starter Gear101*
- Start date
I got gyno after an 8 week cycle of 250mg test enanth/wk, 100mg Anavar ED, 125mg winny ED, 75-112.5mg fina ED, 20-60mg nolv ED
strangly enough, the gyno didn't start till like 8 or 10 weeks after I stopped my cycle though!!! My nips started hurting about two months after my cycle ended so I started taking nolv again @ 60mg ED and that didn't help. After dealing with the pain for about a month or so I got some arimidex and tried 1mg ED for a few weeks and that didn't work. So out of desperation I started taking 5mg of arimidex ED along with 60mg nolv ED and 50-100mg clomid ED; after about 7-10 days at that dosage it stopped and the lump that was a size of the marble at the time shrunk to the size of a pea. I don't understand it. I have done test at 1.5GRAMS/wk for 8 weeks before and 60mg nolv ED and didn't get gyno. I got puffy nips, but no lumps and no pain like I was dealing with after my fina cycle. Now I have a pea sized lump behind my right nipple. I don't know what it could be from being that it was so long after I finished my cycle, but if I had to guess I'd attribute it to the progesterone from the fina....I know alot of you out there think fina doesn't cause gyno. I am not saying it does, and I could be wrong about it aromatizing into prog, but something in that cycle gave it to me or something from my bodies reaction to it.,,,,bigjosh
strangly enough, the gyno didn't start till like 8 or 10 weeks after I stopped my cycle though!!! My nips started hurting about two months after my cycle ended so I started taking nolv again @ 60mg ED and that didn't help. After dealing with the pain for about a month or so I got some arimidex and tried 1mg ED for a few weeks and that didn't work. So out of desperation I started taking 5mg of arimidex ED along with 60mg nolv ED and 50-100mg clomid ED; after about 7-10 days at that dosage it stopped and the lump that was a size of the marble at the time shrunk to the size of a pea. I don't understand it. I have done test at 1.5GRAMS/wk for 8 weeks before and 60mg nolv ED and didn't get gyno. I got puffy nips, but no lumps and no pain like I was dealing with after my fina cycle. Now I have a pea sized lump behind my right nipple. I don't know what it could be from being that it was so long after I finished my cycle, but if I had to guess I'd attribute it to the progesterone from the fina....I know alot of you out there think fina doesn't cause gyno. I am not saying it does, and I could be wrong about it aromatizing into prog, but something in that cycle gave it to me or something from my bodies reaction to it.,,,,bigjosh
I heard bromo is the only way to stop Fina Gyno also.....no nolva, arimidex, liquidex etc. Not sure where to get bromo myself but will need to get some in the next few months before I start some Fina.
I habe also heard a few people complain of bloat off Fina!!! I thought there wasw little chance of bloating but someseem to report that as well. That is exactly why I like the sound of Fina....no bloat....now i hear different from some others
I habe also heard a few people complain of bloat off Fina!!! I thought there wasw little chance of bloating but someseem to report that as well. That is exactly why I like the sound of Fina....no bloat....now i hear different from some others
mr456
New member
Never had any bloat off Fina. I had some gyno symtoms on my last cycle that I though were Test related (was on Fina 80mg EOD Prop 150 EOD) But Nolv. didn't seem to do shit....after my 10th week I dropped the Fina but stayed on Prop and the symtoms magically disappered...so I am thinkin I am prone to gyno from Fina myself.
Small...I thought you posted an article way back when stating that the best way to stop Fina gyno from occuring was to discontinue usage immeadiately?...........456
Small...I thought you posted an article way back when stating that the best way to stop Fina gyno from occuring was to discontinue usage immeadiately?...........456
superchicken
New member
i was getting real puffy nips and a small lump under one at 100mg ed fina, i started my t3 and it went away quickly,.
DecaDent*
New member
The usual initial adult dosage of bromocriptine for the treatment of dysfunctions associated with hyperprolactinemia such as hypogonadism, and/or infertility in males is 1.25 or 2.5 mg daily. Dosage may be increased in increments of 2.5 mg daily at 3- to 7-day intervals as tolerated until the desired therapeutic response is achieved. The usual therapeutic dosage is 5—7.5 mg daily but ranges from 2.5—15 mg daily. Up to 30 mg daily has been required in some . For the treatment of hypogonadism in hyperprolactinemic males, dosages up to 40 mg daily have occasionally been used. The manufacturer states that dosage should not exceed 100 mg daily.
Bromocriptine transiently increases growth hormone secretion in individuals with normal growth hormone concentrations but paradoxically causes sustained suppression of growth hormone secretion in some patients with acromegaly. Following discontinuance of bromocriptine therapy in patients with acromegaly, plasma growth hormone concentrations return to pretreatment concentrations within 2 weeks. Bromocriptine does not affect the release of any other anterior pituitary hormones
For example in the treatment of Acromegaly:
To reduce growth hormone concentrations in adults with acromegaly, the usual initial bromocriptine dosage is 1.25 or 2.5 mg daily at bedtime for 3 days. The manufacturer states that dosage should not exceed 100 mg daily.
It's also has alot of sides......here's a good summary of the most important ones.The incidence of adverse effects associated with bromocriptine mesylate therapy is quite high, especially at the beginning of treatment and with dosages greater than 20 mg daily. Adverse effects are usually mild to moderate and can be minimized by starting with small doses, increasing dosage gradually to effective levels, and administering the drug with food and in the evening. .
Healthy individuals seem to be the most sensitive to adverse effects . About 70% of patients receiving the drug for hyperprolactinemic disorders experience adverse effects; discontinuance of the drug was necessary in 5% of such patients.
GI Effects
Nausea occurs frequently in patients receiving bromocriptine. Nausea has been reported in about 50 or 20% of patients receiving the drug for hyperprolactinemic disorders or acromegaly, respectively. Vomiting, anorexia, abdominal cramps or discomfort, epigastric pain, indigestion or dyspepsia, constipation during long-term use, or diarrhea occurs less frequently. These adverse GI effects may be relieved by temporary reduction of dosage or administration of the drug with food. Peptic ulcer, possibly as a result of increased gastric acid secretion; GI hemorrhage has also been reported.
Nervous System Effects
Adverse nervous system effects of bromocriptine include headache, migraine, dizziness, drowsiness, fatigue, insomnia, lightheadedness, faintness, fainting, and sedation. Headache or dizziness occurs in about 20 or less than 2% of patients receiving the drug for hyperprolactinemic disorders or acromegaly, respectively. Confusion, hallucinations, delusions (usually paranoid), nightmares, and erythromelalgia may occur, Abnormal involuntary movements, “on-off” phenomenon, asthenia, ataxia, mental depression, epileptiform seizure, anxiety, nervousness, and paresthesia. Mania also has been reported in several patients without parkinsonian syndrome receiving bromocriptine; after the drug was discontinued, mania was treated successfully with haloperidol. Patients receiving the drug for acromegaly have also experienced decreased sleep requirements, visual hallucinations, lassitude, sluggishness, paresthesia, vertigo, delusional psychosis, paranoia, heavy headedness, and tingling of the ears.One patient receiving bromocriptine experienced a relapse of severe depression with suicidal thoughts and another developed anxiety and extreme agitation; these effects are similar to those seen with levodopa and are probably caused by dopamine receptor stimulation. Therefore, bromocriptine may be contraindicated in patients with preexisting psychiatric disorders..Seizures and stroke have been associated with bromocriptine )
Cardiovascular Effects
A persistent hypotensive effect commonly accompanies bromocriptine mesylate treatment, and the drug may produce postural hypotension, syncope, and severe prolonged hypotension or shock. Exacerbation of angina may occur. Other adverse cardiovascular effects reported include palpitation, arrhythmia, ventricular tachycardia, bradycardia, and erythematous and edematous ankles and feet. Cold-induced vasospasm with pallor of fingers and toes has been reported in patients receiving 20—60 mg of bromocriptine daily; when the drug was discontinued, vasospasm was reversed and pain did not occur during recovery. Exacerbation of Raynaud’s syndrome and decreased tolerance to cold have also occurred. The drug’s vasodilating action on renal arteries may produce diuresis in some patients. Very high dosages of bromocriptine (100 mg daily) may cause cardiac dysrhythmia. One patient receiving 35 mg of bromocriptine daily for 8 weeks developed paroxysmal breathlessness and acute left ventricular failure associated with atrial flutter-fibrillation; . Occasionally, supine systolic blood pressure has decreased by as much as 50—60 mm Hg in these women. ; Potentially fatal cerebrovascular accident (stroke) (mean onset about 13 days postpartum), principally in postpartum women whose prenatal and obstetric courses were uncomplicated; and acute myocardial infarction have occurred rarely in women receiving the drug for postpartum lactation. Some of these women had toxemia of pregnancy (including postpartum eclampsia) and some (including at least one fatality) received concomitant therapy with other ergot alkaloids or other drugs that can increase blood pressure. Accumulating reports of such adverse effects when the drug was used for postpartum lactation prevention include 31 cases of stoke, 9 of which were fatal, and 63 cases of seizures; no other potential cause for stroke or seizures could be identified in 40% of these cases.While the absolute incidence and relative risk (the ratio of the incidence of these bromocriptine-associated effects to the background of such effects occurring in the postpartum period in women not receiving the drug) remain to be clearly defined, FDA’s Fertility and Maternal Health Drugs Advisory Committee concluded that the possibility of serious adverse effects associated with use of bromocriptine for postpartum lactation prevention outweighs the limited benefits of such therapy.Many postpartum patients who developed stroke and/or seizures in associated with bromocriptine therapy complained of constant and often progressively severe headaches hours to days prior to the acute event. Some such patients also developed prodromal visual disturbances (blurred vision and transient cortical blindness). At least one case of stroke was associated with sagittal sinus thrombosis, and another was associated with cerebral and cerebellar vasculitis. At least one case of acute myocardial infarction was associated with unexplained disseminated intravascular thrombosis, and another was associated with concomitant use of another ergot alkaloid. Most of the women who developed hypertension became normotensive only after discontinuance of therapy with the drug; in 2 patients who were rechallenged, hypertension recurred in one and remained elevated during the entire week of rechallenge. Seizures also resolved following discontinuance of bromocriptine. . In addition, postpartum hypertension or eclampsia as an adverse effect with other ergot alkaloids has been well documented.Bromocriptine should not be used in patients with uncontrolled hypertension or toxemia of pregnancy. Because the risks of serious adverse effects (e.g., hypertensive crisis, seizures, stroke) outweigh the limited benefits of bromocriptine therapy for the prevention of postpartum lactation, such use no longer is recommended.(See Uses: Other Uses. Periodic monitoring of blood pressure, especially during the first weeks of bromocriptine therapy and particularly during the postpartum period, is prudent. . FDA states that similar hypertensive crises have not been reported with other drugs used to suppress lactation to date; however, reporting bias may contribute to this difference. Acute myocardial infarction also has occurred in at least one patient not receiving the drug for the prevention of lactation.
Other Adverse Effects
Other reported adverse effects of bromocriptine include leg cramps, dry mouth, metallic taste, anorexia, burning discomfort of the eyes, blepharospasm, diplopia or other visual disturbances, nasal congestion, rash, mottling of the skin, facial pallor, and urticaria. Hair loss, vasovagal attack, muscle cramps, and potentiation of the effects of alcohol have also occurred rarely in patients with acromegaly.Pulmonary infiltrates, pleural effusion, and thickening of the pleura have been reported in a few patients receiving bromocriptine in dosages ranging from 20—100 mg daily for 6—36 months. . Shortness of breath has been reported rarely. Retroperitoneal fibrosis also has been reported in a few patients receiving bromocriptine in dosages ranging from 30—140 mg daily for 2—10 years.Signs and symptoms of ergotism such as tingling of fingers, cold feet, numbness, muscle cramps of feet and legs, or exacerbation of Raynaud’s syndrome have been reported rarely in patients receiving bromocriptine for the treatment of parkinsonian syndrome. Urinary frequency, urinary incontinence, and urinary retention have also been reported rarely in these patients.Bromocriptine therapy has caused transient increases in serum concentrations of AST (SGOT), ALT (SGPT), Gamma-glutamyl transferase (Gamma-glutamyltranspeptidase, GGT, GGTP), creatine kinase (CK, creatine phosphokinase, CPK), alkaline phosphatase, uric acid, and BUN.
Bromocriptine transiently increases growth hormone secretion in individuals with normal growth hormone concentrations but paradoxically causes sustained suppression of growth hormone secretion in some patients with acromegaly. Following discontinuance of bromocriptine therapy in patients with acromegaly, plasma growth hormone concentrations return to pretreatment concentrations within 2 weeks. Bromocriptine does not affect the release of any other anterior pituitary hormones
For example in the treatment of Acromegaly:
To reduce growth hormone concentrations in adults with acromegaly, the usual initial bromocriptine dosage is 1.25 or 2.5 mg daily at bedtime for 3 days. The manufacturer states that dosage should not exceed 100 mg daily.
It's also has alot of sides......here's a good summary of the most important ones.The incidence of adverse effects associated with bromocriptine mesylate therapy is quite high, especially at the beginning of treatment and with dosages greater than 20 mg daily. Adverse effects are usually mild to moderate and can be minimized by starting with small doses, increasing dosage gradually to effective levels, and administering the drug with food and in the evening. .
Healthy individuals seem to be the most sensitive to adverse effects . About 70% of patients receiving the drug for hyperprolactinemic disorders experience adverse effects; discontinuance of the drug was necessary in 5% of such patients.
GI Effects
Nausea occurs frequently in patients receiving bromocriptine. Nausea has been reported in about 50 or 20% of patients receiving the drug for hyperprolactinemic disorders or acromegaly, respectively. Vomiting, anorexia, abdominal cramps or discomfort, epigastric pain, indigestion or dyspepsia, constipation during long-term use, or diarrhea occurs less frequently. These adverse GI effects may be relieved by temporary reduction of dosage or administration of the drug with food. Peptic ulcer, possibly as a result of increased gastric acid secretion; GI hemorrhage has also been reported.
Nervous System Effects
Adverse nervous system effects of bromocriptine include headache, migraine, dizziness, drowsiness, fatigue, insomnia, lightheadedness, faintness, fainting, and sedation. Headache or dizziness occurs in about 20 or less than 2% of patients receiving the drug for hyperprolactinemic disorders or acromegaly, respectively. Confusion, hallucinations, delusions (usually paranoid), nightmares, and erythromelalgia may occur, Abnormal involuntary movements, “on-off” phenomenon, asthenia, ataxia, mental depression, epileptiform seizure, anxiety, nervousness, and paresthesia. Mania also has been reported in several patients without parkinsonian syndrome receiving bromocriptine; after the drug was discontinued, mania was treated successfully with haloperidol. Patients receiving the drug for acromegaly have also experienced decreased sleep requirements, visual hallucinations, lassitude, sluggishness, paresthesia, vertigo, delusional psychosis, paranoia, heavy headedness, and tingling of the ears.One patient receiving bromocriptine experienced a relapse of severe depression with suicidal thoughts and another developed anxiety and extreme agitation; these effects are similar to those seen with levodopa and are probably caused by dopamine receptor stimulation. Therefore, bromocriptine may be contraindicated in patients with preexisting psychiatric disorders..Seizures and stroke have been associated with bromocriptine )
Cardiovascular Effects
A persistent hypotensive effect commonly accompanies bromocriptine mesylate treatment, and the drug may produce postural hypotension, syncope, and severe prolonged hypotension or shock. Exacerbation of angina may occur. Other adverse cardiovascular effects reported include palpitation, arrhythmia, ventricular tachycardia, bradycardia, and erythematous and edematous ankles and feet. Cold-induced vasospasm with pallor of fingers and toes has been reported in patients receiving 20—60 mg of bromocriptine daily; when the drug was discontinued, vasospasm was reversed and pain did not occur during recovery. Exacerbation of Raynaud’s syndrome and decreased tolerance to cold have also occurred. The drug’s vasodilating action on renal arteries may produce diuresis in some patients. Very high dosages of bromocriptine (100 mg daily) may cause cardiac dysrhythmia. One patient receiving 35 mg of bromocriptine daily for 8 weeks developed paroxysmal breathlessness and acute left ventricular failure associated with atrial flutter-fibrillation; . Occasionally, supine systolic blood pressure has decreased by as much as 50—60 mm Hg in these women. ; Potentially fatal cerebrovascular accident (stroke) (mean onset about 13 days postpartum), principally in postpartum women whose prenatal and obstetric courses were uncomplicated; and acute myocardial infarction have occurred rarely in women receiving the drug for postpartum lactation. Some of these women had toxemia of pregnancy (including postpartum eclampsia) and some (including at least one fatality) received concomitant therapy with other ergot alkaloids or other drugs that can increase blood pressure. Accumulating reports of such adverse effects when the drug was used for postpartum lactation prevention include 31 cases of stoke, 9 of which were fatal, and 63 cases of seizures; no other potential cause for stroke or seizures could be identified in 40% of these cases.While the absolute incidence and relative risk (the ratio of the incidence of these bromocriptine-associated effects to the background of such effects occurring in the postpartum period in women not receiving the drug) remain to be clearly defined, FDA’s Fertility and Maternal Health Drugs Advisory Committee concluded that the possibility of serious adverse effects associated with use of bromocriptine for postpartum lactation prevention outweighs the limited benefits of such therapy.Many postpartum patients who developed stroke and/or seizures in associated with bromocriptine therapy complained of constant and often progressively severe headaches hours to days prior to the acute event. Some such patients also developed prodromal visual disturbances (blurred vision and transient cortical blindness). At least one case of stroke was associated with sagittal sinus thrombosis, and another was associated with cerebral and cerebellar vasculitis. At least one case of acute myocardial infarction was associated with unexplained disseminated intravascular thrombosis, and another was associated with concomitant use of another ergot alkaloid. Most of the women who developed hypertension became normotensive only after discontinuance of therapy with the drug; in 2 patients who were rechallenged, hypertension recurred in one and remained elevated during the entire week of rechallenge. Seizures also resolved following discontinuance of bromocriptine. . In addition, postpartum hypertension or eclampsia as an adverse effect with other ergot alkaloids has been well documented.Bromocriptine should not be used in patients with uncontrolled hypertension or toxemia of pregnancy. Because the risks of serious adverse effects (e.g., hypertensive crisis, seizures, stroke) outweigh the limited benefits of bromocriptine therapy for the prevention of postpartum lactation, such use no longer is recommended.(See Uses: Other Uses. Periodic monitoring of blood pressure, especially during the first weeks of bromocriptine therapy and particularly during the postpartum period, is prudent. . FDA states that similar hypertensive crises have not been reported with other drugs used to suppress lactation to date; however, reporting bias may contribute to this difference. Acute myocardial infarction also has occurred in at least one patient not receiving the drug for the prevention of lactation.
Other Adverse Effects
Other reported adverse effects of bromocriptine include leg cramps, dry mouth, metallic taste, anorexia, burning discomfort of the eyes, blepharospasm, diplopia or other visual disturbances, nasal congestion, rash, mottling of the skin, facial pallor, and urticaria. Hair loss, vasovagal attack, muscle cramps, and potentiation of the effects of alcohol have also occurred rarely in patients with acromegaly.Pulmonary infiltrates, pleural effusion, and thickening of the pleura have been reported in a few patients receiving bromocriptine in dosages ranging from 20—100 mg daily for 6—36 months. . Shortness of breath has been reported rarely. Retroperitoneal fibrosis also has been reported in a few patients receiving bromocriptine in dosages ranging from 30—140 mg daily for 2—10 years.Signs and symptoms of ergotism such as tingling of fingers, cold feet, numbness, muscle cramps of feet and legs, or exacerbation of Raynaud’s syndrome have been reported rarely in patients receiving bromocriptine for the treatment of parkinsonian syndrome. Urinary frequency, urinary incontinence, and urinary retention have also been reported rarely in these patients.Bromocriptine therapy has caused transient increases in serum concentrations of AST (SGOT), ALT (SGPT), Gamma-glutamyl transferase (Gamma-glutamyltranspeptidase, GGT, GGTP), creatine kinase (CK, creatine phosphokinase, CPK), alkaline phosphatase, uric acid, and BUN.
madchemist36
New member
mailboxkillR
New member
Damn now I have to do more shopping(GRRRRRRRRRRR)
Similar threads
